Daina Graybosch
Stock Analyst at Leerink Partners
(0.81)
# 3,705
Out of 4,829 analysts
119
Total ratings
34.09%
Success rate
-14.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TSVT 2seventy bio | Downgrades: Market Perform | $9 → $5 | $4.99 | +0.20% | 6 | Mar 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $75.97 | +56.64% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.25 | +60.00% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $3 → $1 | $0.36 | +179.33% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $57.55 | -32.23% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $5 → $3 | $0.59 | +409.60% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.54 | +2,507.08% | 4 | Jan 6, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.04 | +861.54% | 7 | Jan 6, 2023 | |
| AFMD Affimed | Maintains: Outperform | $100 → $60 | $0.69 | +8,659.12% | 7 | Dec 12, 2022 | |
| IPHA Innate Pharma | Maintains: Outperform | $10 → $9 | $2.44 | +269.06% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $8.28 | +358.94% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.05 | +97.53% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $92.87 | +141.21% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.93 | +1,454.40% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $59 | $6.67 | +785.22% | 7 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.80 | +2,025.53% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.26 | +614.29% | 4 | Feb 25, 2022 |
2seventy bio
Mar 11, 2025
Downgrades: Market Perform
Price Target: $9 → $5
Current: $4.99
Upside: +0.20%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $75.97
Upside: +56.64%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.25
Upside: +60.00%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $3 → $1
Current: $0.36
Upside: +179.33%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $57.55
Upside: -32.23%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $5 → $3
Current: $0.59
Upside: +409.60%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.54
Upside: +2,507.08%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.04
Upside: +861.54%
Affimed
Dec 12, 2022
Maintains: Outperform
Price Target: $100 → $60
Current: $0.69
Upside: +8,659.12%
Innate Pharma
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.44
Upside: +269.06%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $8.28
Upside: +358.94%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.05
Upside: +97.53%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $92.87
Upside: +141.21%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $1.93
Upside: +1,454.40%
May 13, 2022
Maintains: Outperform
Price Target: $60 → $59
Current: $6.67
Upside: +785.22%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.80
Upside: +2,025.53%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.26
Upside: +614.29%